-
Morning Market Movers (DEPO, NPSP, ZNWAW, OREX)
Monday, January 31, 2011 - 11:02am | 148Depomed Inc (NASDAQ: DEPO) shares surged 30.93% to $8.17 at 10:00 am. The Food and Drug Administration (FDA) has approved DEPO's Gralise one-daily tablets for the treatment of post-herpetic neuralgia. NPS Pharmaceuticals Inc (NASDAQ: NPSP) shares advanced 22.08% to $9.29. A Phase 3 trial of NPSP's...
-
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA
Monday, January 31, 2011 - 10:31am | 93AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that NUEDEXTA™ is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA). PBA is a neurologic condition causing...
-
Piper Jaffray Remains Bullish On AGN; Maintains OW Rating, $81 PT
Monday, January 31, 2011 - 10:30am | 118Piper Jaffray remains bullish on Allergan, Inc.'s (NYSE: AGN) growth prospects, both near- and long-term, and expect that 4Q10 is likely to be another solid quarter (Piper Jaffray is at $0.89, in line with the Street), driven by continued year-over-year growth for key medical aesthetics products...
-
DepoMed Trading Substantially Higher Pre-Market (DEPO)
Monday, January 31, 2011 - 10:28am | 42DepoMed (NASDAQ: DEPO) is trading substantially higher today in pre-market trading. At last check, shares of DEPO were trading at $8.58, up 37.50% from Friday's close. DEPO received FDA approval on Gralise during Friday after-hours trading
-
Piper Jaffray Defends THRX Following Delayed Sell-Off
Monday, January 31, 2011 - 10:15am | 195Piper Jaffray is defending Theravance, Inc. (NASDAQ: THRX) following a delayed sell-off on Friday prompted by Novartis' (NYSE: NVS) decision to not pursue US development of a competing once daily long acting beta agonist (LABA) and inhaled corticosteroid (ICS) combination drug for COPD/Asthma. “...
-
Company News for January 31, 2011 - Corporate Summary
Monday, January 31, 2011 - 10:13am | 707• Arch Coal (NYSE:ACI) reported Q4 EPS of $0.33, ex-items, below the Zacks Consensus Estimate of $0.46 per share. Revenues for the quarter rose 15% to $835.4 million, lower than the Zacks Consensus Estimate of $869.0 million • T. Rowe Price (NASDAQ:TROW) reported Q4 EPS of $0.72, above the Zacks...
-
Company News for January 31, 2011 - Corporate Summary
Monday, January 31, 2011 - 10:09am | 707• Arch Coal (NYSE:ACI) reported Q4 EPS of $0.33, ex-items, below the Zacks Consensus Estimate of $0.46 per share. Revenues for the quarter rose 15% to $835.4 million, lower than the Zacks Consensus Estimate of $869.0 million • T. Rowe Price (NASDAQ:TROW) reported Q4 EPS of $0.72, above the Zacks...
-
Citi Has Hold On Pfizer (PFE)
Monday, January 31, 2011 - 9:59am | 121Citi Investment Research has a Hold rating and a $17 price target on shares of Pfizer Inc. (NYSE: PFE). In a note to clients, Citi writes, "We believe PFE's new CEO could announce a strategic review of its #5 ranked global nutritional business, similar to PFE's Oct. '10 announcement to review...
-
Piper Jaffray Downgrades Ardea Biosciences To Neutral
Monday, January 31, 2011 - 9:45am | 173Piper Jaffray is downgrading Ardea Biosciences (NASDAQ: RDEA) from Overweight to Neutral primarily on valuation. Piper is maintaining its revenue estimates for RDEA594, however the price target declines from $34 to $30 as additional shares from secondary offering reduce EPS in its valuation year...
-
Genzyme to Allow Sanofi-Aventis to Conduct Due Diligence
Monday, January 31, 2011 - 9:37am | 120Genzyme Corp. (NASDAQ: GENZ) announced today that ongoing discussions with Sanofi-Aventis (NYSE: SNY) have progressed to the point where Genzyme's board has authorized the company to enter into a confidentiality agreement with Sanofi-Aventis in order to allow Sanofi to conduct due diligence....
-
Benzinga's Top Pre-Market NASDAQ Losers (SVNT, PTNR, CIEN, PRGO)
Monday, January 31, 2011 - 9:29am | 113Savient Pharmaceuticals Inc (NASDAQ: SVNT) dipped 4.05% to $9 in the pre-market session. SVNT announced proposed offering of $125 million in convertible senior notes. Partner Communications Company (NASDAQ: PTNR) fell 3.44% to $19.35 in the pre-market session. PTNR's PEG ratio is 1.34. Ciena...
-
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
Monday, January 31, 2011 - 9:26am | 120Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG)...
-
Piper Jaffray Downgrades Ardea Biosciences To Neutral, PT To $30
Monday, January 31, 2011 - 8:16am | 29Piper Jaffray has downgraded Ardea Biosciences, Inc. (NASDAQ: RDEA) from Overweight to Neutral and has lowered the price target from $34 to $30.
-
Divergence Started to Form Midday 01-28-2011
Friday, January 28, 2011 - 7:33pm | 911Cusick's Corner The day was confirming a trend down day. This was determined not by just price action but also the fact that volume was high. I saw this divergence start to form into the midday and then the price and volume action in equities confirmed this short-term bearishness in the afternoon...
-
Investment Sentiment Bolstered 01-26-2011
Friday, January 28, 2011 - 7:27pm | 945Cusick's Corner optionsXpress was at the Nasdaq Market Site this morning to celebrate our 10th Anniversary. Several employees along with optionsXpress customers helped Ned Bennett, one of our original founders, ring the opening bell. After the opening ceremonies, we had a detailed website...